title: Treatment-related symptoms during the first year following transperineal 125I prostate implantation.
abstract: OBJECTIVE
  To summarize the urinary, rectal, and sexual symptoms occurring during the first 12 months following 125I prostatic implantation.
  
  
  METHODS
  Thirty-one patients with Stage T1 or T2 prostatic carcinoma were evaluated for morbidity following computed tomography-guided transperineal 125I implants from 1988 to 1991. The median total activity used was 47 mCi (range 35-73 mCi). Toxicity was evaluated using a modification of the Radiation Therapy Oncology Group grading system.
  
  
  RESULTS
  Nocturia was the most common treatment-related symptom, reported by 80% of patients within 2 months after implantation, and persisted at 12 months in 45% of the patients. Mild dysuria developed in 48% of patients within 2 months of implantation; two patients needed analgesics for their dysuria. Terazosin hydrochloride (2-10 mg qd) provided subjective improvement of urinary symptoms in seven of eight patients in whom it was tried. Rectal urgency, soft stools, and increased frequency of bowel movements was reported by 25% of the patients within 1-2 months after implantation. The incidence of asymptomatic rectal bleeding or ulceration occurring at any time after implantation was 47%, but resolved in all patients with expectant treatment. Self-limited ulceration of the rectal mucosal occurred in 16%, but only one patient developed a prostato-rectal fistula, managed with an ileal conduit. Five of the 18 potent patients experienced discomfort on erection or ejaculation, beginning within several weeks of their implant. The discomfort resolved within 6 months in three of the patients, but persisted for 18 and 24 months in the other two.
  
  
  CONCLUSIONS
  125I implantation, as performed in this series, is generally associated with only mild-moderate genitourinary and rectal symptoms that may persist 6 months or more after implantation. Prostatic carcinoma, Brachytherapy, Morbidity.
authors.affiliation: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: L
authors.initials: L
authors.lastname: Kleinberg
authors.forename: K
authors.initials: K
authors.lastname: Wallner
authors.forename: J
authors.initials: J
authors.lastname: Roy
authors.forename: M
authors.initials: M
authors.lastname: Zelefsky
authors.forename: V E
authors.initials: VE
authors.lastname: Arterbery
authors.forename: Z
authors.initials: Z
authors.lastname: Fuks
authors.forename: L
authors.initials: L
authors.lastname: Harrison
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007668:Kidney / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011880:Radiotherapy Planning, Computer-Assisted; D012007:Rectum / Q000528:radiation effects; D012725:Sexual Behavior / Q000187:drug effects; D014057:Tomography, X-Ray Computed
chemical_list: D007457:Iodine Radioisotopes